Soleno Therapeutics: A Transformational 2025 Ahead?
ByAinvest
Tuesday, Feb 3, 2026 9:44 am ET1min read
SLNO--
Soleno Therapeutics (SLNO) stock jumped 9% after management described 2025 as a transformational year, citing early VYKAT XR revenue, upcoming full financial results, and a busy investor conference schedule. Despite the recent 9.75% 1-day share price return, the stock has experienced a 10.28% 30-day and 33.72% 90-day decline. Soleno remains loss-making with $98.675 million in revenue and trades at a large discount to the average analyst price target, raising questions about whether it is a mispriced rare disease story or if future growth is already reflected in the valuation.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet